Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
Clinical trial NCT04729595 · TERMINATED
Trial details
- NCT number
- NCT04729595
- Sponsor
- Adamis Pharmaceuticals Corporation
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-01
- Primary completion
- 2022-09-21
- Enrollment
- 248
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.